Skip to main content
. 2023 Nov 14;11(6):e01151. doi: 10.1002/prp2.1151

FIGURE 1.

FIGURE 1

Study design. Treatment T: potential therapeutic dose of GSK'254 100 mg QD. Treatment ST: supratherapeutic dose of GSK'254 500 mg QD. Treatment P: placebo QD. Treatment M: placebo QD on Days 1–6 and a single dose of moxifloxacin 400 mg on Day 7. GSK'254, GSK3640254; QD, once daily; QTc, corrected QT. aWashout was ≥7 days minus 4 h to allow for scheduling flexibility in the clinic.